Linkage between Innovation and Intellectual Property Rights in Chinese Pharmaceutical Companies
The pharmaceutical industry is a stylistic high-tech industry with characteristics of high-investment, high-risk, huge-profit, long-term and strict government administration. Because pharmaceutical technology innovation (TI) has more explicit knowledge than tacit ones, which makes copy cost lower than innovation investment, this industry is more dependent on Intellectual Property Rights (IPRs) to appropriate innovation. So is especially in the Pro-IPRs era. Due to short history of Patent Law in China, poor innovation competence and IPRs management experience, the situation become more terrible to Chinese pharmaceutical companies (CPhCs). It is very important to reinforce the linkages between TI and IPRs in CPhCs when they are catching up with their foreign counterparts. This article puts forward a linkage theoretic framework for CPhCs to promote its core competitiveness.
ZHAO Yuanliang ZHOU Jizhong
The Graduate University of Chinese Academy of Sciences. Beijing, China
国际会议
The Fifth InternationalSymposium on Management of Technology(ISMOT07)(第五届技术与创新管理国际研讨会)
杭州
英文
655-659
2007-06-01（万方平台首次上网日期，不代表论文的发表时间）